Compare Nutrien Ltd (NTR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Tango Therapeutics Inc. — how do they compare? Nutrien Ltd trades at $69.87 (market cap $33.13B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Nutrien Ltd is far larger — about 8.8× Tango Therapeutics Inc.'s market cap, and Nutrien Ltd pays a 3.16% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 60 Days and Tango Therapeutics Inc. for 0 Days on average.
| NTR | TNGX | |
|---|---|---|
Market Cap | $33.13B | $3.75B |
Volume | 2,165,412 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $32.90 |
52-Week Low | $53.64 | $7.50 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | $44.94B | $2.77B |
Dividend Yield | 3.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTR trades at $69.87, up 2.75% today, with mixed technical signals showing bearish momentum but oversold conditions on some indicators. The company demonstrates solid fundamentals with $26.89B revenue, 8.44% net margin, and attractive valuation ratios including P/E of 14.11. Recent earnings show volatility with Q2 2026 missing estimates but Q1 beating expectations. Analyst sentiment remains positive with 60.61% buy ratings and $77.29 consensus target.
NTR presents a compelling value opportunity with reasonable valuations and strong cash flow generation, though facing headwinds from fertilizer industry challenges and competitive pressures. The stock's current discount to analyst targets suggests potential upside, but investors should monitor execution on cost discipline and volume recovery amid fluctuating commodity prices and geopolitical factors affecting fertilizer markets.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
